Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Depreciation & Amortization (CF) (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $563000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 4.07% to $563000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2025, up 48.37% year-over-year, with the annual reading at $2.2 million for FY2025, 48.37% up from the prior year.
  • Depreciation & Amortization (CF) hit $563000.0 in Q4 2025 for Insight Molecular Diagnostics, down from $584000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $584000.0 in Q3 2025 to a low of $121000.0 in Q1 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $376000.0 across 5 years, with a median of $387500.0 in 2022.
  • Biggest five-year swings in Depreciation & Amortization (CF): surged 269.57% in 2021 and later tumbled 30.44% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $218000.0 in 2021, then skyrocketed by 83.49% to $400000.0 in 2022, then dropped by 24.25% to $303000.0 in 2023, then skyrocketed by 78.55% to $541000.0 in 2024, then grew by 4.07% to $563000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for IMDX at $563000.0 in Q4 2025, $584000.0 in Q3 2025, and $559000.0 in Q2 2025.